Biologics

  • Prabotulinumtoxin A (Botulinum toxin type A) FDA
    Indication
    • Temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients (Approved in KR, US, EU, Canada)
    • Treatment of upper limb spasticity in adult patients (Approved in KR)
    • Temporary improvement in the appearance of moderate to severe lateral canthal lines associated with orbicularis oculi activity in adult patients (Approved in KR)
    • Treatment of blepharospasm associated with dystonia in adult patients (Approved in KR)
    • HI PureTM Technology (KR patent No.13-39349, US Patent No. 9,512,418)
  • Somatropin (human growth hormone)
    Indication
    Growth hormone replacement therapy in adults with growth hormone deficiency
  • Spinal fusion device & Dental sinus lift graft
    Indication
    Bone regeneration
  • rhEPO (recombinant human erythropoietin)
    Indication
    Growth hormone replacement therapy in adults with growth hormone deficiency
  • rhEPO (recombinant human erythropoietin) Albumin-FREE
    Indication
    Anemia in chronic renal failure
  • rhEGF (=recombinant human Epidermal Growth Factor)
    Indication
    Diabetic foot ulcer